Akers Biosciences Share Discussion Threads

[norbus] 01/9/2014 10:14

mcm

seems the option self gift is taking a confidence toll.

[deanroberthunt] 29/8/2014 12:16

another jam tomorrow AIMer.....

[waylander2] 28/8/2014 17:15

Been invested here for quite a few years now. More a case of my heart ruling my head. That said I still believe the products have merit. It also gives me hope in case I lose my current job. I can get a job with Akers as it seems that there is no requirement to actually produce any results. Just talk a good story.
Well that's my rant over, in for the long haul.

[algernon2] 28/8/2014 16:55

Not my favourite share at the moment peeps.
Paging Mr Akers:
"Raymond,wake up and do something clever".
"And stop awarding yourself sweets when you hav'na done any homework laddie".

[mcmather] 22/8/2014 13:22

Aye.

Anyone got the capacity to go to this - good opportunity to (further) quiz the good doctor re the options:

The directors of ANGLE plc (AIM: AGL), Akers Biosciences (AIM: AKR) and Tungsten Corporation (AIM: TUNG) will be presenting:
Wednesday the 3rd September 2014, Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

[norbus] 22/8/2014 12:57

msm

ESP will not get your feeling across; you have to write; you will be sick if they travel back to 8 or 10 now the options are granted. I met these guys 2 years ago; something did not feel right; glad someone else put the brave hat on;

[deanroberthunt] 21/8/2014 12:10

Norbus

I don't know buywell2 from adam, only as a cyber poster here on advfn...
but what I do know having been here for a decade 9this site) is, said poster is more often right than wrong, I reckon 9 times out of 10.

whatever else the cyber is or isn't is irrelevant.

[deanroberthunt] 21/8/2014 08:08

the latter

[mcmather] 20/8/2014 15:40

Nasdaq price - those options at under $4; clear message to any US shareholders who participated in the IPO. If I was the good doctor I would be somewhat embarrassed by those options and, for that matter, those at the IPO price of $5.50. Do they mirror the bullish PR campaign on the go at the moment re TP of $11-$13? Or portray small time line-pocketers??

[rivaldo] 20/8/2014 12:06

LOL. I try my best to educate and inform the masses!

The post-results conference call is well worth a listen:



or:

[buywell2] 20/8/2014 08:27

paucity

now there's a word you don't see much on advfn

Can see the dictionaries being dusted off

[deanroberthunt] 20/8/2014 08:23

wider loss on increased sales, you couldn't make it up.

another one for the Franz Klammer society

[rivaldo] 19/8/2014 15:05

Every broker/analyst has successes and failures. I'd be willing to bet Redchip have their share of both, possibly more of the latter given the concentration on the small/micro-cap sector, which is natural.

AKR/AKER are a microcap trying to cause a stir in a huge universe of companies on the NASDAQ. They need all the exposure they can get to start with post-IPO given the paucity of available help and coverage.

After a while of course the results and announcements will speak for themselves one way or another. To date AKR are doing fine imo.

[norbus] 19/8/2014 09:49

Bravo mcm

Loads of these bucket shops here and over there.. Not saying much for management to associate with crooks

[mcmather] 18/8/2014 18:44

Redchip reiterates TP of $13.85 on 13 Aug 2014


However, post here from the yahoo message board concerning redchip from 28 July 2014:

aker might be a good stock, but red chip has also recommended lpih,which was a pure #$%$ fraud also cbly which has not reported for a year and a half. red chip only recommends if they get paid. watch out

[mcmather] 14/8/2014 20:58

Those options at under $4 are, in my opinion, a disgrace and convey an entirely different message to that of the bullish PR exercise that is ongoing here.

If possible they should be rescinded but particularly when considering that $80m worth of development has already been spent here and that the recent funds raised were to effectively oversee the commercialisation of the products; how can those awarded the options fail? What will they have really done to deserve the same and which are over 30% below what investors paid at the IPO stage just a few months earlier??

[rivaldo] 13/8/2014 07:50

Cheers mcmather. Comments here from the CEO - noting that they beat analyst expectations (now edited to give a proper link to Proactive):

http ://www.proactiveinvestors.co.uk/companies/news/71213/update-akers-biosciences-gaining-momentum-71213.html

"Speaking to Proactive Investors, Ray Akers highlighted three aspects of the performance that particularly pleased him.

"First, we beat analyst expectations, which is always good to do, and we're also really pleased with the big increase in international sales and the large initial order out of 36S [the company's distributor: Thirty Six Strategies] into the Middle East and Australia; they [36S] are very bullish on the prospects – it's almost a million dollars they've thrown their hat in the ring with – and we're really excited about it too; it shows there is a nice big market there.

"Thirdly, we're most pleased with something that I've been telling people for a long time now: we're not a one-trick pony. We have multiple products capable of hitting a home run, and while we saw a slow-down in sales of our breathalysers into France, we've got other products coming through enjoying success, and that's exactly what's happened."

The company generated zero revenues in the second quarter from ChubeWorkx, the distributor of the breathalyser product, having accounted for US$766,379 in the first quarter.

Akers is hopeful that the gendarmes will start taking a firmer line once supply bottlenecks for breathalysers have eased.

In contrast, revenue from 36S was US$864,000, up from zero a year earlier so, as Akers indicated, it a case of swings and roundabouts.

Shares in Akers finished the day up 1.1% at 232.5p."

[mcmather] 12/8/2014 23:44

Lastly, year end will tell with the company continues with a dual listing. AIM is apparently far cheaper than Nasdaq. Interesting to see what happens on that front.

[mcmather] 12/8/2014 23:41

SUMMARY

Chube – sales down.
PIFA Heparin/PF4 Rapid Assay products – sales up a bit.
Tri-Cholesterol - $864k order but formal product approval still awaited by 36S.
Hoping for some sales of PIFA Heparin/PF4 Rapid Assay products & Breath Ketone in Europe as the 2014 goes on.
Formal approval of the PIFA PF4 / Pluss should arrive in China in Q4 2014; currently there is an emergency approval but reference to this being "introductory" (??) and therefore not generating revenue.
Hopefully we will hear something shortly re the agreement with "Jai" in India to market the Company's PIFA Heparin/Platelet Factor-4 Rapid Assay, PIFA Dengue Assay, Battlefield Blood Transfusion Card and Tri-Cholesterol rapid tests.
Still saying comfortable with $5m revenue for the year. H1 2014 saw revenue of $2,527,076 (H1 2013: $2,661,669) – ie same again for H2 2014 to achieve $5m but that saw a net loss of $1,090,595.
Some one off costs relating to the Nasdaq listing but significant improvement is required from the management and the sales teams in my opinion. Some of those costs are plain giddy.
Those options at under $4 is pure wrong / greed in my opinion; I would have a very poor opinion of those behind this if I had participated in the nasdaq listing at $5.50. Shocking that.

[mcmather] 12/8/2014 23:15

Some other potential notables:

At June 30, 2014, ABI had cash of $402,282 working capital of $14,267,869.

The Company entered into an agreement with an outside product and design firm on July 14, 2014 to work with internal personnel to review and further develop the VIVO product line.

The Company is currently pursuing ISO certification of it quality management system which would allow the Company to meet the regulatory requirements for product sales in large, international markets (e.g. India).